198 related articles for article (PubMed ID: 26359417)
21. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
22. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.
Sideris M; Adams K; Moorhead J; Diaz-Cano S; Bjarnason I; Papagrigoriadis S
Anticancer Res; 2015 Apr; 35(4):2345-50. PubMed ID: 25862899
[TBL] [Abstract][Full Text] [Related]
25. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
[TBL] [Abstract][Full Text] [Related]
26. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
27. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
Sclafani F; Gullo G; Sheahan K; Crown J
Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
[TBL] [Abstract][Full Text] [Related]
29. Somatic BRAF-V600E mutations in familial colorectal cancer.
Vandrovcova J; Lagerstedt-Robinsson K; Påhlman L; Lindblom A
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2270-3. PubMed ID: 17119056
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
31. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues.
Chat-Uthai N; Vejvisithsakul P; Udommethaporn S; Meesiri P; Danthanawanit C; Wongchai Y; Teerapakpinyo C; Shuangshoti S; Poungvarin N
PLoS One; 2018; 13(6):e0198795. PubMed ID: 29879227
[TBL] [Abstract][Full Text] [Related]
32. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
Eisenhardt AE; Olbrich H; Röring M; Janzarik W; Anh TN; Cin H; Remke M; Witt H; Korshunov A; Pfister SM; Omran H; Brummer T
Int J Cancer; 2011 Nov; 129(9):2297-303. PubMed ID: 21190184
[TBL] [Abstract][Full Text] [Related]
33. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
Vakiani E; Yaeger R; Brooke S; Zhou Y; Klimstra DS; Shia J
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):438-43. PubMed ID: 25517872
[TBL] [Abstract][Full Text] [Related]
35. BRAF
Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
[TBL] [Abstract][Full Text] [Related]
36. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients.
Vlajnic T; Andreozzi MC; Schneider S; Tornillo L; Karamitopoulou E; Lugli A; Ruiz C; Zlobec I; Terracciano L
Mod Pathol; 2011 Oct; 24(10):1404-12. PubMed ID: 21743435
[TBL] [Abstract][Full Text] [Related]
37.
Jones JC; Renfro LA; Al-Shamsi HO; Schrock AB; Rankin A; Zhang BY; Kasi PM; Voss JS; Leal AD; Sun J; Ross J; Ali SM; Hubbard JM; Kipp BR; McWilliams RR; Kopetz S; Wolff RA; Grothey A
J Clin Oncol; 2017 Aug; 35(23):2624-2630. PubMed ID: 28486044
[TBL] [Abstract][Full Text] [Related]
38. High frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran.
Asl JM; Almasi S; Tabatabaiefar MA
Pak J Biol Sci; 2014 Apr; 17(4):565-9. PubMed ID: 25911848
[TBL] [Abstract][Full Text] [Related]
39. Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.
Obaid NM; Bedard K; Huang WY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282860
[TBL] [Abstract][Full Text] [Related]
40. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
